The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Expression and clinical significance of C1orf63 in breast cancer
Pages: 420-422
Year: Issue:  6
Journal: Journal of International Oncology

Abstract: Objective To investigate the expression and clinical significance of C1orf63 in breast cancer.Methods Sixty-seven breast cancer tissues and adjacent non-cancerous tissues were collected,and the expression of C1orf63 was detected by immunohistochemistry.The relationships between C1orf63 and clinical pathological characteristics were examined withx2 test.Independent prognostic factors were performed by theCox regression model.Results Positive cytoplasmic expression of C1orf63 was observed in 21 (31.3%) of 67 primary tumors,but not in their matched adjacent non-cancerous tissues,with significant difference (x2 =24.90,P < 0.01).There were no relationships between C1orf63 and age (x2 =0.06,P =0.79),T stage (x2 =0.50,P =0.47),N stage (x2 =1.41,P =0.23),TNM stage (x2 =0.29,P =0.58),estrogen receptor (x2=0.82,P =0.36),progesterone receptor (x2=0.31,P =0.57),and human epidermal growth factor receptor 2 (Her2) expression (x2 =0.00,P =0.98).Multivariate analysis demonstrated N stage (HR =4.96,95%CI:2.03-12.15,P<0.01) and C1orf63 (HR=2.37,95%CI:1.05-5.37,P=0.04) were unfavorable prognostic factors.Conclusion The high expression of C1orf63 in breast cancer may indicate poor prognosis.
Related Articles
No related articles found